JPMorgan Chase & Co. Cuts Humana (NYSE:HUM) Price Target to $256.00

Humana (NYSE:HUM) had its price objective decreased by JPMorgan Chase & Co. from $257.00 to $256.00 in a research note issued to investors on Tuesday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the insurance provider’s stock.

HUM has been the subject of several other research reports. Wells Fargo & Company dropped their price target on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th. Royal Bank of Canada restated an “outperform” rating and set a $283.00 price target on shares of Humana in a report on Wednesday, February 12th. Morgan Stanley reduced their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Finally, Piper Sandler upped their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Nineteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $285.68.

Humana Price Performance

Humana stock opened at $257.24 on Tuesday. Humana has a one year low of $213.31 and a one year high of $406.46. The business has a fifty day moving average price of $270.62 and a 200-day moving average price of $292.21. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market capitalization of $30.97 billion, a P/E ratio of 22.78, a PEG ratio of 2.11 and a beta of 0.56.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, equities research analysts forecast that Humana will post 16.11 EPS for the current year.

Insider Activity at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.32% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Humana

A number of hedge funds have recently added to or reduced their stakes in HUM. Sunbelt Securities Inc. increased its stake in shares of Humana by 49.3% in the 4th quarter. Sunbelt Securities Inc. now owns 609 shares of the insurance provider’s stock worth $155,000 after purchasing an additional 201 shares in the last quarter. GTS Securities LLC boosted its holdings in shares of Humana by 104.5% during the 4th quarter. GTS Securities LLC now owns 1,256 shares of the insurance provider’s stock valued at $319,000 after purchasing an additional 29,057 shares during the last quarter. Vise Technologies Inc. boosted its holdings in shares of Humana by 8.0% during the 4th quarter. Vise Technologies Inc. now owns 873 shares of the insurance provider’s stock valued at $221,000 after purchasing an additional 65 shares during the last quarter. Focus Partners Advisor Solutions LLC bought a new position in shares of Humana in the 4th quarter valued at about $387,000. Finally, Continuum Advisory LLC lifted its holdings in shares of Humana by 4.3% in the 4th quarter. Continuum Advisory LLC now owns 14,202 shares of the insurance provider’s stock valued at $3,603,000 after acquiring an additional 590 shares during the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.